Medincell Shares Advance Following Positive UZEDY® Clinical Data and Upgraded Revenue Outlook

Opening

Medincell (EPA: MEDCL, OTC: MDCLF) shares experienced a substantial increase following the announcement of new clinical data regarding UZEDY®, its long-acting injectable for schizophrenia, partnered with Teva (TA: TEVA.TA). The data indicates improved patient outcomes and significant cost efficiencies, leading to a notable market reaction within the pharmaceutical sector.

The Event in Detail

New data, showcased in one of ten schizophrenia-related posters presented by Medincell’s partner Teva at the 2025 Psych Congress, revealed that initiating UZEDY® in hospitalized schizophrenia patients was associated with a 2.89-day shorter length of hospital stay compared to Janssen Pharmaceuticals, Inc.'s Invega Sustenna®. This translates to an estimated direct cost saving of $3,200 per hospitalization.

Furthermore, a majority of Healthcare Practitioners (HCPs) expressed a preference for UZEDY® over Invega Sustenna® across several factors, including ease of administration, initiation, dosing characteristics, and subcutaneous injection features. Following this news, Medincell's U.S. OTC-traded stock (MDCLF) surged by +100.69%.

Analysis of Market Reaction

The robust market reaction stems from UZEDY®'s demonstrated clinical differentiation and economic benefits. In a healthcare landscape increasingly focused on value-based care, the ability to reduce hospital stays and associated costs is a critical advantage. UZEDY®'s superior clinical profile, including no reported cases of Post-injection Delirium/Sedation Syndrome (PDSS), subcutaneous administration, and flexible dosing options (monthly/bi-monthly), enhances clinician preference and patient adherence. Real-world adherence rates stand at 69%, with 41% of patients covered by Medicaid, highlighting its accessibility and utility in vulnerable populations.

Teva, Medincell's commercial partner, reported UZEDY® sales of $54 million in Q2 2025, a 2.2-fold increase compared to Q2 2024. The revenue outlook for 2025 has been raised to $190–$200 million, up from approximately $160 million, signaling strong integration into hospital formularies and positive investor sentiment.

Broader Context and Implications

UZEDY®'s success positions it as a transformative player in the long-acting injectable (LAI) antipsychotic market, which is estimated to be a $4.5 billion segment. The drug's ability to drive significant cost savings directly impacts healthcare system expenditures, making it an attractive option for payers and providers.

Medincell reported a 2.8x increase in overall revenue for the fiscal year ending March 31, 2025, primarily fueled by UZEDY®'s strong performance, with royalties reaching €6.5 million, a 3.8x increase year-over-year. The company has also successfully cut operational losses in half, moving closer to anticipated operational profitability by fiscal year 2027. This financial strengthening and UZEDY®'s market penetration underscore the strategic importance of Medincell's BEPO® technology, potentially paving the way for wider adoption of its other pipeline assets.

Expert Commentary

Christophe Douat, CEO of Medincell, affirmed the company's trajectory, stating,

"2024 marked the beginning of a new era with a surge in revenues, notably fueled by the strong performance of UZEDY®."

This sentiment aligns with the positive market reaction and revised sales forecasts, underscoring the product's significant impact on both patient care and company financials.

Looking Ahead

Investors will be closely monitoring Medincell's pipeline development, particularly the investigational 1-Month Long-Acting Injectable Olanzapine (mdc-TJK / TEV-749), for which an New Drug Application (NDA) submission to the FDA is anticipated in Q4 2025. This represents another significant opportunity for Medincell to expand its share in the LAI market, especially given olanzapine's status as the most prescribed antipsychotic in the U.S. Positive efficacy results from its Pivotal Phase 3 trial were presented in May and September 2024, with study completion in January 2025.

Additionally, an sNDA for a new additional indication in bipolar disorder for UZEDY® is currently under review by the FDA after acceptance in February 2025, potentially broadening its market reach. The company's strengthened balance sheet and ongoing patent protections (until 2042 for UZEDY® and 2044 for the olanzapine formulation) also provide a stable foundation for future growth in the biotechnology sector.